Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
107.5 USD | -0.92% | -0.91% | +71.63% |
10:41pm | U.S. FDA advisers back approval for Guardant's cancer test | RE |
May. 14 | Piper Sandler Adjusts Price Target on Natera to $120 From $110, Maintains Overweight Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+71.63% | 13.33B | |
+16.49% | 83.4B | |
-29.52% | 72.11B | |
0.00% | 27.04B | |
-13.29% | 16.96B | |
+1.03% | 16.86B | |
+1.57% | 15.76B | |
+1.53% | 12.76B | |
+70.68% | 12.74B | |
+1.11% | 12.32B |
- Stock Market
- Equities
- NTRA Stock
- News Natera, Inc.
- Transcript : Natera, Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-13-2023 02